Notable Price Action: Is Aegerion Pharmaceuticals, Inc.’s Fuel For Real? The Stock Just Increased Again

Notable Price Action: Is Aegerion Pharmaceuticals, Inc.'s Fuel For Real? The Stock Just Increased Again

The stock of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is a huge mover today! About 1.60M shares traded hands or 541.54% up from the average. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has declined 39.29% since April 26, 2016 and is downtrending. It has underperformed by 44.55% the S&P500.
The move comes after 6 months positive chart setup for the $58.13 million company. It was reported on Nov, 29 by Barchart.com. We have $2.12 PT which if reached, will make NASDAQ:AEGR worth $2.91 million more.

Analysts await Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) to report earnings on February, 23. They expect $-0.33 earnings per share, up 62.92% or $0.56 from last year’s $-0.89 per share. After $-0.46 actual earnings per share reported by Aegerion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -28.26% EPS growth.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Ratings Coverage

Out of 5 analysts covering Aegerion Pharmaceuticals (NASDAQ:AEGR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Aegerion Pharmaceuticals has been the topic of 9 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The company was upgraded on Wednesday, November 11 by Bank of America. The stock has “Underperform” rating given by Bank of America on Friday, February 12. Jefferies upgraded the shares of AEGR in a report on Tuesday, July 28 to “Buy” rating. The firm has “Buy” rating by Guggenheim given on Monday, December 21. Zacks upgraded it to “Hold” rating and $21 target price in Friday, August 7 report.

According to Zacks Investment Research, “Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is used as an oral once-a-day treatment for patients with severe lipid disorders. Implitapide is used in the treatment of hypertriglyceridemia. Aegerion Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey.”

More recent Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) news were published by: Globenewswire.com which released: “Aegerion Pharmaceuticals, Inc. and QLT Inc. Complete Merger Transaction; QLT …” on November 29, 2016. Also Bostonglobe.com published the news titled: “Aegerion Pharmaceuticals to merge with Canadian drug maker” on June 15, 2016. Fool.com‘s news article titled: “Why Aegerion Pharmaceuticals Is Crashing Today” with publication date: November 10, 2015 was also an interesting one.

AEGR Company Profile

Aegerion Pharmaceuticals, Inc., incorporated on February 4, 2005, is a biopharmaceutical company. The Firm is engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Firm operates through pharmaceuticals segment. The Company’s products include lomitapide and metreleptin.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment